16 stories mentioning A
Every FINWIRES story that references A, newest first.
Agilent Technologies (A) has an average rating of overweight and mean price target of $162.13, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $135.28, Change: $-0.70, Percent Change: -0.52%
Healthcare stocks rose late Thursday afternoon, with the NYSE Healthcare Index rising 1.4% and the State Street Health Care Select Sector SPDR ETF (XLV) adding 1.5%.The iShares Biotechnology ETF (IBB) climbed 1.5%.In corporate news, Eli Lilly's (LLY) weight-loss drugs secured coverage from the three largest US pharmacy benefit managers, the drugmaker said Thursday. Lilly shares gained 4.3%.Agilent Technologies (A) stock jumped 18% after the company posted higher fiscal Q2 adjusted earnings and revenue, and raised its fiscal 2026 adjusted EPS guidance.Illumina (ILMN) shares climbed 5% after it said it launched a whole-genome sequencing research workflow for molecular residual disease detection.AstraZeneca's (AZN) durvalumab, plus Bacillus Calmette-Guerin, received approval by the Food and Drug Administration to treat adults with BCG-naive, high-risk non-muscle invasive bladder cancer, the FDA said Thursday. AstraZeneca shares rose 0.2%.
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We raise our 12-month target price from $120 to $150, 22.7x of our FY 27 EPS estimate, between A's three- and five-year historical forward averages of 21.2x and 23.3x, respectively. We raise our FY 26 EPS estimate from $5.97 to $6.04 and our FY 27 estimate from $6.57 to $6.60. Shares rallied sharply on Q2 FY 26 results that beat expectations, supported by margin expansion and a boost to financial guidance despite lingering headwinds across China, the Middle East, small/mid-size biotech, and academic/government end markets. Though we think A's gradually improving sales mix toward more services/consumables is positive, we also note that instruments (34% of Q2 revenue) saw its ninth straight quarter of order book-to-bill ratio above 1.0, supported by the ongoing instrument replacement cycle. In March, A announced a $950M acquisition of clinical pathology and antibody business Biocare Medical, which is expected to be accretive to both sales and earnings and via a higher margin product mix.
Healthcare stocks rose Thursday afternoon, with the NYSE Healthcare Index rising 1.1% and the State Street Health Care Select Sector SPDR ETF (XLV) adding 1.2%.The iShares Biotechnology ETF (IBB) increased 1.1%.In corporate news, Eli Lilly's (LLY) weight-loss drugs secured coverage from the three largest US pharmacy benefit managers, the drugmaker said Thursday. Lilly shares gained 3.6%.Agilent Technologies (A) stock jumped 19% after the company posted higher fiscal Q2 adjusted earnings and revenue, and raised its fiscal 2026 adjusted EPS guidance.Illumina (ILMN) shares climbed 4.9% after it said it launched a whole-genome sequencing research workflow for molecular residual disease detection.Cogent Biosciences (COGT) shares added 2.4% after it said the US Food and Drug Administration has accepted its new drug application for bezuclastinib plus sunitinib to treat patients with gastrointestinal stromal tumors who have been treated with imatinib previously.
Agilent Technologies (A) has an average rating of overweight and mean price target of $162.13, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $136.00, Change: $+20.16, Percent Change: +17.40%
Agilent Technologies (A) is benefiting from broad-based product cycle momentum and resilient end-market exposure across pharmaceuticals, diagnostics and industrial segments, RBC Capital said in a Wednesday note.The analysts said the company's fiscal Q2 results reflected strong execution, with revenue and segment performance coming in ahead of expectations, driven by strength in key instrument platforms and non-healthcare markets such as advanced materials and semiconductors.Management raised 2026 guidance and analysts lifted 2026 to 2027 estimates, citing product cycle momentum and reshoring capex, with semiconductor-related sales at 3% to 4% of revenue growing mid-teens and strength in advanced materials markets, according to the report.RBC highlighted strength in the company's Applied Markets and Life Sciences & Diagnostics segments, driven by pharma and biotech demand, with weakness in academic and government offset by gains in semiconductors, advanced materials and reshoring-related investment.The brokerage firm noted that multiple product cycles, including new platform launches, are driving a synchronized upcycle at Agilent Technologies, with sustained high-single-digit growth increasingly achievable despite tougher comparisons ahead.RBC maintained its outperform rating on the stock and raised its price target to $155 from $153.Shares of Agilent Technologies were up more than 16% in Thursday trading.Price: $135.14, Change: $+19.30, Percent Change: +16.66%
Agilent Technologies (A) is an "increasingly attractive" asset that posted a solid fiscal Q2 beat as key drivers like liquid and gas chromatography instruments continue to deliver amid solid execution across the board, BofA Securities said in a Thursday research note.Instrument segment momentum in Q2 was linked with share gains and execution as management highlighted continued competitive wins and innovation-driven displacements, analysts wrote.Gas chromatography replacement activity amid aging fleets supported the robust chemical print in Q2, the firm said. Overall, spectroscopy remained a standout across semiconductor, high-purity chemical, and advanced materials workflows, according to analysts.The brokerage said it upgraded the stock to buy from neutral and adjusted its price target to $145 per share from $150.Price: $134.37, Change: $+18.53, Percent Change: +16.00%
Healthcare stocks were mixed premarket Thursday, with the iShares Biotechnology ETF (IBB) down 0.5% and the State Street Health Care Select Sector SPDR ETF (XLV) 0.1% higher.Agilent Technologies (A) stock was up more than 12% after the company posted higher fiscal Q2 adjusted earnings and revenue, and raised its fiscal 2026 adjusted EPS guidance.Zenas BioPharma (ZBIO) shares were up more than 1% after the company said it submitted a biologics license application to the US Food and Drug Administration for obexelimab in immunoglobulin G4-related disease, a chronic fibro-inflammatory disease affecting multiple organ systems.Sanofi (SNY) has been granted US Food and Drug Administration priority review for a new drug application for venglustat for the treatment of type 3 Gaucher disease, a rare disorder, the company said. Sanofi shares were 0.8% lower pre-bell.
Healthcare stocks were steady premarket Thursday, with the iShares Biotechnology ETF (IBB) inactive and the State Street Health Care Select Sector SPDR ETF (XLV) up a slight 0.1%.Agilent Technologies (A) stock was up more than 11% after the company posted higher fiscal Q2 adjusted earnings and revenue, and raised its full-year adjusted EPS guidance.
Agilent Technologies (A) has an average rating of overweight and mean price target of $161.80, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Agilent beat Q2 expectations with revenue of $1.83B rising 10% Y/Y (+6.3% core), topping the $1.80B consensus, while adjusted EPS of $1.49 grew 14% Y/Y, beating the $1.41 forecast. Operating leverage was notable with adjusted operating margin expanding 130 bps Y/Y to 26.4%, driven by broad-based business growth across Americas (+11%) and Europe (+8%). We view the strong performance positively, supported by ongoing instrument replacement cycles and strength in Agilent's cancer diagnostics portfolio, with Life Sciences and Diagnostics sales rising 12% Y/Y. Management raised FY 26 guidance across all key metrics, increasing revenue guidance by 30 bps at the midpoint to $7.39-7.49B (up 6.3-7.8% reported, 4.5-6.0% core) and non-GAAP EPS guidance by $0.08 to $6.00-6.10. We expect continued momentum from pharma end markets (+6% core growth) and Applied Markets (+14% revenue growth), though academic/government weakness persists with core sales down 5% Y/Y on uncertain NIH funding policy.
Agilent Technologies (A) reported fiscal Q2 adjusted earnings late Wednesday of $1.49 per diluted share, up from $1.31 a year earlier.Analysts polled by FactSet expected $1.41.Revenue in the three months ended April 30 rose to $1.84 billion from $1.67 billion a year earlier.Analysts surveyed by FactSet expected $1.8 billion.Agilent expects Q3 adjusted EPS of $1.48 to $1.50 on revenue of $1.83 billion to $1.85 billion. Analysts project EPS of $1.50 on revenue of $1.83 billion.The company boosted full-year guidance to adjusted EPS of $6 to $6.10 on revenue of $7.39 billion to $7.49 billion. The prior forecast was EPS of $5.90 to $6.04 on revenue of $7.3 billion to $7.5 billion.Analysts expect EPS of $5.97 on revenue of $7.39 billion.Agilent shares rose 6.7% in after-hours trading.
Agilent Technologies (A) is facing product cycle momentum across key instrument platforms, with tailwinds from drug manufacturing exposure amid US pharmaceutical reshoring, RBC Capital Markets said in a note emailed Wednesday.The company's newly launched instruments have early commercial traction, as evidenced by the growth of its liquid chromatography and single-quad mass spectrometry, RBC said, noting that a synchronized upcycle in key platforms can be a growth driver.In addition, Agilent expects the US pharma reshoring to present a $1 billion boon for analytical instruments, the firm noted. RBC said the company has about a 25% sales exposure to this opportunity with its analytical tools used for quality control and specialty contract manufacturing services.Agilent is set to release its fiscal Q2 results after the stock market closes on Wednesday.RBC Capital Markets initiated coverage of Agilent, with an outperform rating and a $153 price target.Price: $115.50, Change: $+0.42, Percent Change: +0.36%
Agilent Technologies (A) has an average rating of overweight and mean price target of $160.73, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)
Agilent Technologies (A) has an average rating of overweight and mean price target of $161.21, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $115.35, Change: $+0.56, Percent Change: +0.49%
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lower our 12-month price target from $140 to $120, reflecting an 18.3x P/E multiple of our unchanged FY 27 (Oct.) EPS estimate of $6.57 (FY 26 EPS estimate raised $0.01 to $5.97), a discount to Agilent's one- and three-year historical forward averages of 20.2x and 21.2x, respectively. We think headwinds may persist across key life sciences end markets due to macroeconomic pressures, uncertain tariff and research funding policy, and weaker biotech spending and clinical trial activity. Our target multiple is near recent forward valuations for key life sciences tools & services peers Danaher Corporation (DHR), Thermo Fisher Scientific Inc. (TMO), Waters Corporation (WAT), and Revvity Inc. (RVTY). The sub-industry recently traded at a roughly 25% discount to its three-year historical forward average. Agilent will report Q2 FY 26 earnings after the market close on May 27, when we anticipate 7.5%-8.0% comparable growth in both sales and EPS.